|
WO2021072351A1
|
|
Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations
|
|
WO2020223197A1
|
|
Diagnosis and treatment of autism spectrum disorders associated with altered metabolic pathways
|
|
US2021072230A1
|
|
In vitro assay to predict cardiotoxicity
|
|
US2020348319A1
|
|
Diagnosis and treatment of autism spectrum disorders based on amine containing metabotypes
|
|
US2019178900A1
|
|
Autism subsets
|
|
CA2917483A1
|
|
Biomarkers of autism spectrum disorder
|
|
CN104822843A
|
|
Predicting of human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
|
|
AU2011248464A1
|
|
Metabolic biomarkers of autism
|
|
AU2011232577A1
|
|
Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
|
